EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neonatal impact of maternal biomarker screening for risk of preterm birth with targeted interventions (PRIME): A multicenter, randomized, controlled trial

Brian K Iriye iD, John M O'Brien iD, Christopher S Ennen iD, Perry S Barrilleaux iD, Jill A Berkin iD, Anna Palatnik iD, Moeun Son iD, Cynthia Gyamfi-Bannerman iD, Mollie McDonnold iD, Glenn R Markenson iD, Anthony C Sciscione, Joseph R Biggio iD und 6 weitere

Pregnancy · 2026-01 · 2 (1)

DOI: 10.1002/pmf2.70202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pregnancy, online erschienen am 06.01.2026. Verfasst von Brian K Iriye und 17 weiteren Autor:innen. Beteiligte Einrichtung: High Risk Pregnancy Center Hera Women's Health Las Vegas Nevada USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preterm birth remains a leading cause of neonatal morbidity and mortality, yet clinicians possess limited tools to identify at‐risk pregnancies and implement effective interventions. This study evaluated whether knowledge of a mid‐second‐trimester maternal blood biomarker test result, combined with an intervention bundle for those identified as being at higher risk, improves neonatal outcomes in a population at low overall risk for spontaneous preterm birth.

Methods

PRIME was a multicenter, randomized, controlled trial at 19 US sites. Participants with singleton pregnancies at 18–20 6/7 weeks’ gestation underwent biomarker testing with the previously validated insulin‐like growth factor‐binding protein 4 to sex hormone‐binding globulin (IGFBP4/SHBG) ratio and were randomized to an open‐label screen‐guided care arm or a blinded routine care arm. Higher‐risk participants in the screen‐guided care arm received a bundled intervention consisting of daily vaginal progesterone, low‐dose aspirin, and weekly telephonic nurse support. The co‐primary outcomes, analyzed in an intent‐to‐treat population, were: (1) a composite index of neonatal morbidity and mortality and (2) neonatal hospital length of stay. Additional outcomes were gestational age at birth, neonatal intensive care unit (NICU) admissions, and NICU length of stay. Outcomes were adjusted for parity, pre‐enrollment aspirin use, and COVID positivity. Recruitment was halted for efficacy at the interim analysis, and all enrolled participants were followed to delivery and neonatal outcome assessment.

Results

The enrolled population included 5018 participants with delivery data available for 4806, comprising the intent‐to‐treat population (2416 screen‐guided care, 2390 routine care). Screen‐guided care was associated with reduced composite neonatal morbidity (odds ratio [OR], 0.80; 95% confidence interval [CI], 0.66–0.96; p = 0.015), shortened neonatal hospital stays (incidence rate ratio [IRR], 0.95; 95% CI, 0.92–0.98; p = 0.004), and fewer NICU admissions.

Conclusion

In low‐risk pregnancies, care guided by a maternal IGFBP4/SHBG blood test with targeted interventions improved neonatal outcomes. These findings suggest a potential role for IGFBP4/SHBG screen‐guided care in enhancing early risk detection and informing strategies to reduce events related to preterm birth. Trial Registration ClinicalTrials.gov identifier: NCT04301518

Schlagwörter

Stichwörter der Autor:innen

biomarker screeningcare managementlow‐dose aspirinneonatal intensive care unit (NICU)neonatal morbiditypreterm birthvaginal progesterone

Autor:innen und Institutionen

  • High Risk Pregnancy Center Hera Women's Health Las Vegas Nevada USA.
  • Department of Obstetrics and Gynecology University of Kentucky Health Care Lexington Kentucky USA.
  • Department of Obstetrics and Gynecology, University of Virginia School of Medicine Charlottesville Virginia USA.
  • Department of Obstetrics and Gynecology Louisiana State University Health Science Center Shreveport Louisiana USA.
  • Department of Obstetrics, Gynecology, and Reproductive Science Icahn School of Medicine at Mount Sinai New York New York USA.
  • Department of Obstetrics and Gynecology Medical College of Wisconsin Milwaukee Wisconsin USA.

ORCID-Profile: Brian K Iriye, John M O'Brien, Christopher S Ennen, Perry S Barrilleaux, Jill A Berkin, Anna Palatnik, Moeun Son, Cynthia Gyamfi-Bannerman, Mollie McDonnold, Glenn R Markenson, Joseph R Biggio, Scott A Sullivan, Michael Walker, Babak Shahbaba

Zitieren

APA

Iriye, B. K., O'Brien, J. M., Ennen, C. S., Barrilleaux, P. S., Berkin, J. A., Palatnik, A., Son, M., Gyamfi-Bannerman, C., McDonnold, M., Markenson, G. R., Sciscione, A. C., Biggio, J. R., Wolf, S., Sullivan, S. A., Walker, M., Shahbaba, B., Godt, J., & Pound, S. P. (2026). Neonatal impact of maternal biomarker screening for risk of preterm birth with targeted interventions (PRIME): A multicenter, randomized, controlled trial. Pregnancy, 2(1). https://doi.org/10.1002/pmf2.70202

Vancouver

Iriye BK, O'Brien JM, Ennen CS, Barrilleaux PS, Berkin JA, Palatnik A, et al. Neonatal impact of maternal biomarker screening for risk of preterm birth with targeted interventions (PRIME): A multicenter, randomized, controlled trial. Pregnancy. 2026;2(1). doi:10.1002/pmf2.70202

BibTeX
@article{Iriye2026,
  author = {Iriye, Brian K and O'Brien, John M and Ennen, Christopher S and Barrilleaux, Perry S and Berkin, Jill A and Palatnik, Anna and Son, Moeun and Gyamfi-Bannerman, Cynthia and McDonnold, Mollie and Markenson, Glenn R and Sciscione, Anthony C and Biggio, Joseph R and Wolf, Samuel and Sullivan, Scott A and Walker, Michael and Shahbaba, Babak and Godt, Jannik and Pound, Stephen P},
  title = {Neonatal impact of maternal biomarker screening for risk of preterm birth with targeted interventions (PRIME): A multicenter, randomized, controlled trial},
  journal = {Pregnancy},
  year = {2026},
  volume = {2},
  number = {1},
  doi = {10.1002/pmf2.70202}
}
Kostenlos starten →